Literature DB >> 22791939

Kidneys in chronic liver diseases.

Marek Hartleb, Krzysztof Gutkowski.   

Abstract

Acute kidney injury (AKI), defined as an abrupt increase in the serum creatinine level by at least 0.3 mg/dL, occurs in about 20% of patients hospitalized for decompensating liver cirrhosis. Patients with cirrhosis are susceptible to developing AKI because of the progressive vasodilatory state, reduced effective blood volume and stimulation of vasoconstrictor hormones. The most common causes of AKI in cirrhosis are pre-renal azotemia, hepatorenal syndrome and acute tubular necrosis. Differential diagnosis is based on analysis of circumstances of AKI development, natriuresis, urine osmolality, response to withdrawal of diuretics and volume repletion, and rarely on renal biopsy. Chronic glomerulonephritis and obstructive uropathy are rare causes of azotemia in cirrhotic patients. AKI is one of the last events in the natural history of chronic liver disease, therefore, such patients should have an expedited referral for liver transplantation. Hepatorenal syndrome (HRS) is initiated by progressive portal hypertension, and may be prematurely triggered by bacterial infections, nonbacterial systemic inflammatory reactions, excessive diuresis, gastrointestinal hemorrhage, diarrhea or nephrotoxic agents. Each type of renal disease has a specific treatment approach ranging from repletion of the vascular system to renal replacement therapy. The treatment of choice in type 1 hepatorenal syndrome is a combination of vasoconstrictor with albumin infusion, which is effective in about 50% of patients. The second-line treatment of HRS involves a transjugular intrahepatic portosystemic shunt, renal vasoprotection or systems of artificial liver support.

Entities:  

Keywords:  Acute kidney injury; Chronic liver disease; Chronic renal failure; Liver cirrhosis

Mesh:

Substances:

Year:  2012        PMID: 22791939      PMCID: PMC3386317          DOI: 10.3748/wjg.v18.i24.3035

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  153 in total

Review 1.  High-risk situations and procedures.

Authors:  Christoph R Becker; Charles Davidson; Norbert Lameire; Peter A McCullough; Fulvio Stacul; James Tumlin; Andy Adam
Journal:  Am J Cardiol       Date:  2006-02-20       Impact factor: 2.778

Review 2.  Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.

Authors:  P Deltenre; P Mathurin; S Dharancy; R Moreau; P Bulois; J Henrion; F R Pruvot; O Ernst; J C Paris; D Lebrec
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

3.  Which patients benefit from hemodialysis therapy in hepatorenal syndrome?

Authors:  Oliver Witzke; Markus Baumann; Daniel Patschan; Susann Patschan; Anna Mitchell; Ulrich Treichel; Guido Gerken; Thomas Philipp; Andreas Kribben
Journal:  J Gastroenterol Hepatol       Date:  2004-12       Impact factor: 4.029

4.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Authors:  Richard Moreau; Francois Durand; Thierry Poynard; Christian Duhamel; Jean-Paul Cervoni; Philippe Ichaï; Armand Abergel; Chantal Halimi; Mathieu Pauwels; Jean-Pierre Bronowicki; Emile Giostra; Cathy Fleurot; Danielle Gurnot; Olivier Nouel; Philippe Renard; Michel Rivoal; Pierre Blanc; Dimitri Coumaros; Sylvie Ducloux; Stephane Levy; Alexandre Pariente; Jean-Marc Perarnau; Jean Roche; Myriam Scribe-Outtas; Dominique Valla; Brigitte Bernard; Didier Samuel; Joël Butel; Antoine Hadengue; Andrzej Platek; Didier Lebrec; Jean-Francois Cadranel
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

5.  Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  D Sansonno; L Gesualdo; C Manno; F P Schena; F Dammacco
Journal:  Hepatology       Date:  1997-05       Impact factor: 17.425

6.  Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.

Authors:  K M Peltekian; F Wong; P P Liu; A G Logan; M Sherman; L M Blendis
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

7.  The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.

Authors:  Georgios Kalambokis; Michalis Economou; Andreas Fotopoulos; Jihad Al Bokharhii; Christos Pappas; Afroditi Katsaraki; Epameinondas V Tsianos
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

8.  Octreotide in liver cirrhosis: a salvage for variceal bleeding can be a gunshot for kidneys.

Authors:  Deniz Güney Duman; Davut Tüney; Serpil Bilsel; Fehime Benli; Sehnaz Karan; Erol Avsar; Osman Ozdogan; Nurdan Tözün
Journal:  Liver Int       Date:  2005-06       Impact factor: 5.828

Review 9.  Refractory ascites.

Authors:  B A Runyon
Journal:  Semin Liver Dis       Date:  1993-11       Impact factor: 6.115

10.  Coronary artery disease in patients with liver cirrhosis.

Authors:  Evangelos Kalaitzakis; Annika Rosengren; Tomas Skommevik; Einar Björnsson
Journal:  Dig Dis Sci       Date:  2009-02-26       Impact factor: 3.199

View more
  21 in total

1.  Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome.

Authors:  Jing-Bo Wang; Hai-Tao Wang; Lu-Ping Li; Ying-Chun Yan; Wei Wang; Jing-Yang Liu; Yi-Tong Zhao; Wei-Shu Gao; Ming-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 2.  Outcomes of liver transplantation in patients with hepatorenal syndrome.

Authors:  Rohan M Modi; Nishi Patel; Sherif N Metwally; Khalid Mumtaz
Journal:  World J Hepatol       Date:  2016-08-28

Review 3.  Renal dysfunction in patients with cirrhosis: Where do we stand?

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 4.  Acute kidney injury in patients with chronic liver disease.

Authors:  Nicolas Rognant
Journal:  World J Hepatol       Date:  2015-05-08

Review 5.  Comorbidity in cirrhosis.

Authors:  Peter Jepsen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 6.  Renal failure in cirrhosis: Emerging concepts.

Authors:  Paulo Lisboa Bittencourt; Alberto Queiroz Farias; Carlos Terra
Journal:  World J Hepatol       Date:  2015-09-28

Review 7.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

Review 8.  The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations.

Authors:  Farnad Imani; Mahsa Motavaf; Saeid Safari; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2014-10-11       Impact factor: 0.660

Review 9.  Neutrophil Gelatinase Associated Lipocalin (NGAL) - a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof?

Authors:  S G Firu; C T Streba; D Firu; D E Tache; I Rogoveanu
Journal:  J Med Life       Date:  2015

10.  The 24 hour urine creatinine clearance for prediction of glomerular filtration rate in liver cirrhosis patients: have we considered all elements?

Authors:  Mohammad Kazem Fallahzadeh; Neeraj Singh
Journal:  Hepat Mon       Date:  2013-07-17       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.